SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fredun Pharmaceuticals shines on getting nod to manufacture Xenografts

15 Mar 2022 Evaluate

Fredun Pharmaceuticals is currently trading at Rs. 955.00, up by 45.05 points or 4.95% from its previous closing of Rs. 909.95 on the BSE.

The scrip opened at Rs. 929.95 and has touched a high and low of Rs. 955.00 and Rs. 929.95 respectively. So far 1852 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1140.00 on 31-Jan-2022 and a 52 week low of Rs. 351.20 on 23-Aug-2021.

Last one week high and low of the scrip stood at Rs. 955.00 and Rs. 778.00 respectively. The current market cap of the company is Rs. 422.87 crore.

The promoters holding in the company stood at 51.27%, while Institutions and Non-Institutions held 1.69% and 47.04% respectively.

Fredun Pharmaceuticals has received the approval for manufacturing Xenografts for various Dental and Orthopaedic surgical appliances from Central Drugs Standard Control Organisation (COSCO), India. With this, the Company aims to penetrate the Dental fraternity across India. With many doctors now using grafts, company expanding product portfolio with this new addition to take advantage of the growing opportunity.

Fredun Pharmaceuticals was established to produce drugs of international standards at affordable prices. The company produces anti -bacterial, anti-malarial, anti-diabetic tablets, capsules and dry syrups.

Fredun Pharma Share Price

2108.00 64.10 (3.14%)
22-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.50
Dr. Reddys Lab 1216.60
Cipla 1235.00
Zydus Lifesciences 928.00
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×